Oxford Biomedica plc (OTCPK:OXBDF) has signed an 18-month supply agreement under a three-year master supply and development contract with AstraZeneca (NYSE:AZN) for the large-scale commercial manufacture of COVID-19 vaccine AZD1222.
By mutual agreement, the supply period may be extended for an additional 18 months.
Under the terms of the deal, AZN will pay Oxford £15M upfront as a capacity reservation fee. Assuming all goes according to plan, Oxford expects to receive more than £35M in additional revenue plus certain materials costs for the production of multiple large-scale batches of AZN1222 until year-end 2021.
Oxford will reserve capacity for AZN in up to three suites in the Group’s new 7,800 sq. meter manufacturing center, OxBox, for the initial 18-month period. The new GMP facility can accommodate up to 1,000-liter scale.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.